APO Research
Talk to an analyst

APO RESEARCH · REPORT

Anti-herpesvirus Agent

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Anti-herpesvirus Agent Market Outlook and Growth Opportunities 2026

30 December 2025193 pages

Choose your research edition.

Industry ResearchAnti-herpesvirus Agent Industry Research Report 2026100 pages · $2,950 USDIndustry Growth & TrendsGlobal Anti-herpesvirus Agent Industry Growth and Trends Forecast to 203262 pages · $3,450 USDMarket StructureGlobal Anti-herpesvirus Agent Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032175 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Anti-herpesvirus Agent Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Anti-herpesvirus Agent Market Analysis and Forecast 2026-2032192 pages · $4,950 USD

Market perspective

The global Anti-herpesvirus Agent market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Anti-herpesvirus Agent is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Anti-herpesvirus Agent is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Anti-herpesvirus Agent is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Anti-herpesvirus Agent market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Anti-herpesvirus Agent market include Maruho Co., Ltd., Asahi Kasei Corporation and AiCuris, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Anti-herpesvirus Agent market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Anti-herpesvirus Agent and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Anti-herpesvirus Agent revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Anti-herpesvirus Agent market.

Anti-herpesvirus Agent Segment by Company

Maruho Co., Ltd.

Asahi Kasei Corporation

AiCuris

Anti-herpesvirus Agent Segment by Type

Amenamevir

Famciclovir

Anti-herpesvirus Agent Segment by Application

Medical Field

Other

Anti-herpesvirus Agent Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Anti-herpesvirus Agent status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Anti-herpesvirus Agent key companies, revenue, market share, and recent developments.

3. To split the Anti-herpesvirus Agent breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Anti-herpesvirus Agent market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Anti-herpesvirus Agent significant trends, drivers, influence factors in global and regions.

6. To analyze Anti-herpesvirus Agent competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Anti-herpesvirus Agent market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Anti-herpesvirus Agent and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Anti-herpesvirus Agent.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Anti-herpesvirus Agent industry.

Chapter 3: Detailed analysis of Anti-herpesvirus Agent company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Anti-herpesvirus Agent in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Anti-herpesvirus Agent in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Anti-herpesvirus Agent Industry Trends Table 2. Anti-herpesvirus Agent Industry Drivers Table 3. Anti-herpesvirus Agent Industry Opportunities and Challenges Table 4. Anti-herpesvirus Agent Industry Restraints Table 5. Global Anti-herpesvirus Agent Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Anti-herpesvirus Agent Revenue Share by Company (2021-2026) Table 7. Global Anti-herpesvirus Agent Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Anti-herpesvirus Agent Key Company Manufacturing Base & Headquarters Table 9. Global Anti-herpesvirus Agent Company, Product Type & Application Table 10. Global Anti-herpesvirus Agent Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Anti-herpesvirus Agent by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Amenamevir Table 15. Significant Companies of Famciclovir Table 16. Global Anti-herpesvirus Agent Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global Anti-herpesvirus Agent Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global Anti-herpesvirus Agent Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global Anti-herpesvirus Agent Sales Value Share by Type (2021-2026) Table 20. Global Anti-herpesvirus Agent Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Medical Field Table 22. Significant Companies of Other Table 23. Global Anti-herpesvirus Agent Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 24. Global Anti-herpesvirus Agent Sales Value by Application (2021-2026) & (US$ Million) Table 25. Global Anti-herpesvirus Agent Sales Value by Application (2027-2032) & (US$ Million) Table 26. Global Anti-herpesvirus Agent Sales Value Share by Application (2021-2026) Table 27. Global Anti-herpesvirus Agent Sales Value Share by Application (2027-2032) Table 28. Global Anti-herpesvirus Agent Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 29. Global Anti-herpesvirus Agent Sales Value by Region (2021-2026) & (US$ Million) Table 30. Global Anti-herpesvirus Agent Sales Value Share by Region (2021-2026) Table 31. Global Anti-herpesvirus Agent Sales Value by Region (2027-2032) & (US$ Million) Table 32. Global Anti-herpesvirus Agent Sales Value Share by Region (2027-2032) Table 33. Global Anti-herpesvirus Agent Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global Anti-herpesvirus Agent Sales Value by Country (2021-2026) & (US$ Million) Table 35. Global Anti-herpesvirus Agent Sales Value Market Share by Country (2021-2026) Table 36. Global Anti-herpesvirus Agent Sales Value by Country (2027-2032) & (US$ Million) Table 37. Global Anti-herpesvirus Agent Sales Value Market Share by Country (2027-2032) Table 38. Maruho Co., Ltd. Company Information Table 39. Maruho Co., Ltd. Business Overview Table 40. Maruho Co., Ltd. Anti-herpesvirus Agent Revenue (US$ Million) and Gross Margin (2021-2026) Table 41. Maruho Co., Ltd. Anti-herpesvirus Agent Product Portfolio Table 42. Maruho Co., Ltd. Recent Development Table 43. Asahi Kasei Corporation Company Information Table 44. Asahi Kasei Corporation Business Overview Table 45. Asahi Kasei Corporation Anti-herpesvirus Agent Revenue (US$ Million) and Gross Margin (2021-2026) Table 46. Asahi Kasei Corporation Anti-herpesvirus Agent Product Portfolio Table 47. Asahi Kasei Corporation Recent Development Table 48. AiCuris Company Information Table 49. AiCuris Business Overview Table 50. AiCuris Anti-herpesvirus Agent Revenue (US$ Million) and Gross Margin (2021-2026) Table 51. AiCuris Anti-herpesvirus Agent Product Portfolio Table 52. AiCuris Recent Development Table 53. Research Programs/Design for This Report Table 54. Authors List of This Report Table 55. Secondary Sources Table 56. Primary Sources List of Figures Figure 1. Anti-herpesvirus Agent Product Image Figure 2. Global Anti-herpesvirus Agent Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Anti-herpesvirus Agent Market Size (2021-2032) & (US$ Million) Figure 4. Global Anti-herpesvirus Agent Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Amenamevir Image Figure 8. Famciclovir Image Figure 9. Global Anti-herpesvirus Agent Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global Anti-herpesvirus Agent Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global Anti-herpesvirus Agent Sales Value Share by Type (2021-2032) Figure 12. Medical Field Image Figure 13. Other Image Figure 14. Global Anti-herpesvirus Agent Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Anti-herpesvirus Agent Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Anti-herpesvirus Agent Sales Value Share by Application (2021-2032) Figure 17. Global Anti-herpesvirus Agent Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 18. Global Anti-herpesvirus Agent Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 19. North America Anti-herpesvirus Agent Sales Value (2021-2032) & (US$ Million) Figure 20. North America Anti-herpesvirus Agent Sales Value Share by Country (%), 2025 VS 2032 Figure 21. Europe Anti-herpesvirus Agent Sales Value (2021-2032) & (US$ Million) Figure 22. Europe Anti-herpesvirus Agent Sales Value Share by Country (%), 2025 VS 2032 Figure 23. Asia-Pacific Anti-herpesvirus Agent Sales Value (2021-2032) & (US$ Million) Figure 24. Asia-Pacific Anti-herpesvirus Agent Sales Value Share by Country (%), 2025 VS 2032 Figure 25. South America Anti-herpesvirus Agent Sales Value (2021-2032) & (US$ Million) Figure 26. South America Anti-herpesvirus Agent Sales Value Share by Country (%), 2025 VS 2032 Figure 27. Middle East & Africa Anti-herpesvirus Agent Sales Value (2021-2032) & (US$ Million) Figure 28. Middle East & Africa Anti-herpesvirus Agent Sales Value Share by Country (%), 2025 VS 2032 Figure 29. USA Anti-herpesvirus Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 30. USA Anti-herpesvirus Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 31. USA Anti-herpesvirus Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 32. Canada Anti-herpesvirus Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 33. Canada Anti-herpesvirus Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 34. Canada Anti-herpesvirus Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 35. Mexico Anti-herpesvirus Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 36. Mexico Anti-herpesvirus Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 37. Mexico Anti-herpesvirus Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 38. Germany Anti-herpesvirus Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. Germany Anti-herpesvirus Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. Germany Anti-herpesvirus Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. France Anti-herpesvirus Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. France Anti-herpesvirus Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. France Anti-herpesvirus Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. U.K. Anti-herpesvirus Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. U.K. Anti-herpesvirus Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. U.K. Anti-herpesvirus Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Italy Anti-herpesvirus Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Italy Anti-herpesvirus Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Italy Anti-herpesvirus Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Spain Anti-herpesvirus Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Spain Anti-herpesvirus Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Spain Anti-herpesvirus Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Russia Anti-herpesvirus Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Russia Anti-herpesvirus Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Russia Anti-herpesvirus Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Netherlands Anti-herpesvirus Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Netherlands Anti-herpesvirus Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Netherlands Anti-herpesvirus Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Nordic Countries Anti-herpesvirus Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Nordic Countries Anti-herpesvirus Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Nordic Countries Anti-herpesvirus Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. China Anti-herpesvirus Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. China Anti-herpesvirus Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. China Anti-herpesvirus Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Japan Anti-herpesvirus Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Japan Anti-herpesvirus Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Japan Anti-herpesvirus Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. South Korea Anti-herpesvirus Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. South Korea Anti-herpesvirus Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. South Korea Anti-herpesvirus Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. India Anti-herpesvirus Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. India Anti-herpesvirus Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. India Anti-herpesvirus Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. Australia Anti-herpesvirus Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. Australia Anti-herpesvirus Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. Australia Anti-herpesvirus Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Southeast Asia Anti-herpesvirus Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Southeast Asia Anti-herpesvirus Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Southeast Asia Anti-herpesvirus Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Brazil Anti-herpesvirus Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Brazil Anti-herpesvirus Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Brazil Anti-herpesvirus Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Argentina Anti-herpesvirus Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Argentina Anti-herpesvirus Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Argentina Anti-herpesvirus Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Chile Anti-herpesvirus Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Chile Anti-herpesvirus Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Chile Anti-herpesvirus Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Colombia Anti-herpesvirus Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Colombia Anti-herpesvirus Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Colombia Anti-herpesvirus Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Peru Anti-herpesvirus Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Peru Anti-herpesvirus Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Peru Anti-herpesvirus Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Saudi Arabia Anti-herpesvirus Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Saudi Arabia Anti-herpesvirus Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Saudi Arabia Anti-herpesvirus Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Israel Anti-herpesvirus Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Israel Anti-herpesvirus Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Israel Anti-herpesvirus Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. UAE Anti-herpesvirus Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. UAE Anti-herpesvirus Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. UAE Anti-herpesvirus Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Turkey Anti-herpesvirus Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Turkey Anti-herpesvirus Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Turkey Anti-herpesvirus Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Iran Anti-herpesvirus Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Iran Anti-herpesvirus Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Iran Anti-herpesvirus Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Egypt Anti-herpesvirus Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Egypt Anti-herpesvirus Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Egypt Anti-herpesvirus Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Years Considered Figure 114. Research Process Figure 115. Key Executives Interviewed

Scope & coverage.

Types
  • Amenamevir
  • Famciclovir
Applications
  • Medical Field
  • Other
Companies covered
  • Maruho Co., Ltd.
  • Asahi Kasei Corporation
  • AiCuris

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Anti-herpesvirus Agent Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Anti-herpesvirus Agent Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Anti-herpesvirus Agent Market Dynamics
  1. 2.1 Anti-herpesvirus Agent Industry Trends
  2. 2.2 Anti-herpesvirus Agent Industry Drivers
  3. 2.3 Anti-herpesvirus Agent Industry Opportunities and Challenges
  4. 2.4 Anti-herpesvirus Agent Industry Restraints
3 Anti-herpesvirus Agent Market by Company
  1. 3.1 Global Anti-herpesvirus Agent Company Revenue Ranking in 2025
  2. 3.2 Global Anti-herpesvirus Agent Revenue by Company (2021-2026)
  3. 3.3 Global Anti-herpesvirus Agent Company Ranking (2024-2026)
  4. 3.4 Global Anti-herpesvirus Agent Company Manufacturing Base and Headquarters
  5. 3.5 Global Anti-herpesvirus Agent Company Product Type and Application
  6. 3.6 Global Anti-herpesvirus Agent Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Anti-herpesvirus Agent Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Anti-herpesvirus Agent Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Anti-herpesvirus Agent Market by Type
  1. 4.1 Anti-herpesvirus Agent Type Introduction
  2. 4.1.1 Amenamevir
  3. 4.1.2 Famciclovir
  4. 4.2 Global Anti-herpesvirus Agent Sales Value by Type
  5. 4.2.1 Global Anti-herpesvirus Agent Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Anti-herpesvirus Agent Sales Value by Type (2021-2032)
  7. 4.2.3 Global Anti-herpesvirus Agent Sales Value Share by Type (2021-2032)
5 Anti-herpesvirus Agent Market by Application
  1. 5.1 Anti-herpesvirus Agent Application Introduction
  2. 5.1.1 Medical Field
  3. 5.1.2 Other
  4. 5.2 Global Anti-herpesvirus Agent Sales Value by Application
  5. 5.2.1 Global Anti-herpesvirus Agent Sales Value by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Anti-herpesvirus Agent Sales Value by Application (2021-2032)
  7. 5.2.3 Global Anti-herpesvirus Agent Sales Value Share by Application (2021-2032)
6 Anti-herpesvirus Agent Regional Value Analysis
  1. 6.1 Global Anti-herpesvirus Agent Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Anti-herpesvirus Agent Sales Value by Region (2021-2032)
  3. 6.2.1 Global Anti-herpesvirus Agent Sales Value by Region: 2021-2026
  4. 6.2.2 Global Anti-herpesvirus Agent Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Anti-herpesvirus Agent Sales Value (2021-2032)
  7. 6.3.2 North America Anti-herpesvirus Agent Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Anti-herpesvirus Agent Sales Value (2021-2032)
  10. 6.4.2 Europe Anti-herpesvirus Agent Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Anti-herpesvirus Agent Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Anti-herpesvirus Agent Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Anti-herpesvirus Agent Sales Value (2021-2032)
  16. 6.6.2 South America Anti-herpesvirus Agent Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Anti-herpesvirus Agent Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Anti-herpesvirus Agent Sales Value Share by Country, 2025 VS 2032
7 Anti-herpesvirus Agent Country-level Value Analysis
  1. 7.1 Global Anti-herpesvirus Agent Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Anti-herpesvirus Agent Sales Value by Country (2021-2032)
  3. 7.2.1 Global Anti-herpesvirus Agent Sales Value by Country (2021-2026)
  4. 7.2.2 Global Anti-herpesvirus Agent Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Anti-herpesvirus Agent Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Anti-herpesvirus Agent Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Anti-herpesvirus Agent Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Anti-herpesvirus Agent Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Anti-herpesvirus Agent Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Anti-herpesvirus Agent Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Anti-herpesvirus Agent Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Anti-herpesvirus Agent Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Anti-herpesvirus Agent Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Anti-herpesvirus Agent Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Anti-herpesvirus Agent Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Anti-herpesvirus Agent Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Anti-herpesvirus Agent Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Anti-herpesvirus Agent Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Anti-herpesvirus Agent Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Anti-herpesvirus Agent Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Anti-herpesvirus Agent Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Anti-herpesvirus Agent Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Anti-herpesvirus Agent Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Anti-herpesvirus Agent Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Anti-herpesvirus Agent Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Anti-herpesvirus Agent Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Anti-herpesvirus Agent Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Anti-herpesvirus Agent Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Anti-herpesvirus Agent Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Anti-herpesvirus Agent Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Anti-herpesvirus Agent Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Anti-herpesvirus Agent Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Anti-herpesvirus Agent Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Anti-herpesvirus Agent Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Anti-herpesvirus Agent Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Anti-herpesvirus Agent Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Anti-herpesvirus Agent Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Anti-herpesvirus Agent Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Anti-herpesvirus Agent Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Anti-herpesvirus Agent Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Anti-herpesvirus Agent Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Anti-herpesvirus Agent Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Anti-herpesvirus Agent Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Anti-herpesvirus Agent Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Anti-herpesvirus Agent Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Anti-herpesvirus Agent Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Anti-herpesvirus Agent Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Anti-herpesvirus Agent Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Anti-herpesvirus Agent Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Anti-herpesvirus Agent Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Anti-herpesvirus Agent Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Anti-herpesvirus Agent Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Anti-herpesvirus Agent Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Anti-herpesvirus Agent Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Anti-herpesvirus Agent Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Anti-herpesvirus Agent Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Anti-herpesvirus Agent Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Anti-herpesvirus Agent Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Anti-herpesvirus Agent Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Anti-herpesvirus Agent Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Anti-herpesvirus Agent Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Anti-herpesvirus Agent Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Anti-herpesvirus Agent Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Anti-herpesvirus Agent Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Anti-herpesvirus Agent Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Anti-herpesvirus Agent Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Anti-herpesvirus Agent Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Anti-herpesvirus Agent Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Anti-herpesvirus Agent Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Anti-herpesvirus Agent Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Anti-herpesvirus Agent Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Anti-herpesvirus Agent Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Anti-herpesvirus Agent Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Anti-herpesvirus Agent Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Anti-herpesvirus Agent Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Anti-herpesvirus Agent Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Anti-herpesvirus Agent Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Anti-herpesvirus Agent Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Anti-herpesvirus Agent Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Anti-herpesvirus Agent Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Anti-herpesvirus Agent Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Anti-herpesvirus Agent Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Anti-herpesvirus Agent Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Anti-herpesvirus Agent Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Anti-herpesvirus Agent Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Anti-herpesvirus Agent Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Anti-herpesvirus Agent Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Anti-herpesvirus Agent Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Maruho Co., Ltd.
  2. 8.1.1 Maruho Co., Ltd. Company Information
  3. 8.1.2 Maruho Co., Ltd. Business Overview
  4. 8.1.3 Maruho Co., Ltd. Anti-herpesvirus Agent Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Maruho Co., Ltd. Anti-herpesvirus Agent Product Portfolio
  6. 8.1.5 Maruho Co., Ltd. Recent Developments
  7. 8.2 Asahi Kasei Corporation
  8. 8.2.1 Asahi Kasei Corporation Company Information
  9. 8.2.2 Asahi Kasei Corporation Business Overview
  10. 8.2.3 Asahi Kasei Corporation Anti-herpesvirus Agent Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Asahi Kasei Corporation Anti-herpesvirus Agent Product Portfolio
  12. 8.2.5 Asahi Kasei Corporation Recent Developments
  13. 8.3 AiCuris
  14. 8.3.1 AiCuris Company Information
  15. 8.3.2 AiCuris Business Overview
  16. 8.3.3 AiCuris Anti-herpesvirus Agent Revenue and Gross Margin (2021-2026)
  17. 8.3.4 AiCuris Anti-herpesvirus Agent Product Portfolio
  18. 8.3.5 AiCuris Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst